Thalassemiaﾠis a blood disorder passed down through families (inherited) in which the body makes an abnormal form or inadequate amount of hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen. The disorder results in large numbers of red blood cells being destroyed, which leads to anemia. LPI (LP Information)' newest research report, the ﾓThalassemia Industry Forecastﾔ looks at past sales and reviews total world Thalassemia sales in 2022, providing a comprehensive analysis by region and market sector of projected Thalassemia sales for 2023 through 2029. With Thalassemia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Thalassemia industry. This Insight Report provides a comprehensive analysis of the global Thalassemia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Thalassemia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firmsﾒ unique position in an accelerating global Thalassemia market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Thalassemia and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Thalassemia. The global Thalassemia market size is projected to grow from US$ 2948.9 million in 2022 to US$ 5324.4 million in 2029; it is expected to grow at a CAGR of 8.8% from 2023 to 2029. United States market for Thalassemia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. China market for Thalassemia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. Europe market for Thalassemia is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029. Global key Thalassemia players cover Bluebird bio, Inc., Acceleron Pharma, Inc., Celgene Corporation, GlaxoSmithKline plc, Incyte Corporation, Gamida Cell, Kiadis Pharma, La Jolla Pharmaceutical Company and IONIS Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022. This report presents a comprehensive overview, market shares, and growth opportunities of Thalassemia market by product type, application, key players and key regions and countries. Market Segmentation: Segmentation by type Iron Chelating Drugs Others Segmentation by application Hospital Clinic Research Institute Laboratories Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Bluebird bio, Inc. Acceleron Pharma, Inc. Celgene Corporation GlaxoSmithKline plc Incyte Corporation Gamida Cell Kiadis Pharma La Jolla Pharmaceutical Company IONIS Pharmaceuticals
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Thalassemia Market Size 2018-2029 2.1.2 Thalassemia
